ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Aptinyx Inc

Aptinyx Inc (APTX)

0.061
0.00
(0.00%)
Closed May 20 4:00PM
0.00
0.00
(0.00%)

Professional-Grade Tools, for Individual Investors.

APTX News

Official News Only

APTX Discussion

View Posts
Renee Renee 5 months ago
APTX: effective Jan. 2,2024: Company Dissolved/Final Liquidation.

FINRA will delete the symbol:

https://otce.finra.org/otce/dailyList?viewType=Deletions
👍️0
Renee Renee 1 year ago
APTX delisted from the Nasdaq to the OTC:

https://otce.finra.org/otce/dailyList?viewType=Additions
👍️0
surf1944 surf1944 1 year ago
https://stockcharts.com/h-sc/ui?s=aptx&p=D&yr=0&mn=6&dy=0&id=p38090673899

https://www.barchart.com/stocks/quotes/aptx/technical-chart?plot=CANDLE&volume=total&data=DO&density=ML&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;SMA(20);SMA(50);SMA(100);SMA(200);CHKMF(20)&sym=SYSX&grid=1&height=210&studyheight=100

https://www.barchart.com/stocks/quotes/aptx/opinion

Moving again!
👍️0
surf1944 surf1944 1 year ago
https://stockcharts.com/h-sc/ui?s=aptx&p=D&yr=0&mn=6&dy=0&id=p38090673899

https://www.barchart.com/stocks/quotes/aptx/technical-chart?plot=CANDLE&volume=total&data=DO&density=ML&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;SMA(20);SMA(50);SMA(100);SMA(200);CHKMF(20)&sym=SYSX&grid=1&height=210&studyheight=100

https://www.barchart.com/stocks/quotes/aptx/opinion
👍️ 1
glenn1919 glenn1919 1 year ago
APTX.............................https://stockcharts.com/h-sc/ui?s=APTX&p=W&b=5&g=0&id=p86431144783
👍️0
bella99 bella99 1 year ago
Looks like offerings going through Now?????????
👍️0
BeamMeUpScotty BeamMeUpScotty 1 year ago
$50m+ cash in hand so no need for any offerings any time soon. Huge gaps to the up side!
👍️0
BeamMeUpScotty BeamMeUpScotty 1 year ago
Also has huge institutional investors. Takes up two pages! See the link.

Scroll all the way down

https://whalewisdom.com/stock/aptx

This patent is for a treatment for depression which unfortunately is suffered by more and more people every year so the potential market is huge.

Link to the patent.

https://data.epo.org/publication-server/pdf-document?pn=3490992&ki=B1&cc=EP


👍️0
MASTERULTRA MASTERULTRA 1 year ago
NO SHHH... THIS SHIT IS BLOWING UP AND I AM SURPRISED...
👍️0
MASTERULTRA MASTERULTRA 1 year ago
Stocktwit blowing this shit up. Over 10mil in buys AH. HOLYSHIT...
👍️0
BeamMeUpScotty BeamMeUpScotty 1 year ago
Dude if you look at the “tape” there’s a lot of buys still coming in at high of the day after hours!
👍️0
limer814 limer814 1 year ago
Ok shhhhhh
👍️0
THEMASTERS_SON THEMASTERS_SON 1 year ago
Shhhhh…keep it quiet til AM!!!
👍️0
willlbone willlbone 1 year ago
Lowered my bid
to 10 cents.
👍️0
mauiguy2 mauiguy2 3 years ago
Good day yesterday. Any reason for it?
👍️0
Moneta Man Moneta Man 3 years ago
It's one of my favorite quotes from Warren Buffett, the world's most famous value investor: "Price is what you pay; value is what you get." Get ready to get a whole lot of value with APTX going forward. This stock/company is rich with potential!
👍️0
Moneta Man Moneta Man 3 years ago
Status of each clinical study can be found here... https://www.aptinyx.com/clinical-studies/
👍️0
Moneta Man Moneta Man 3 years ago
https://www.smarteranalyst.com/new-blurbs/aptinyx-aptx-receives-a-buy-from-h-c-wainwright/?mod=mw_quote_news
👍️0
Moneta Man Moneta Man 4 years ago
Hoping to learn more about their clinical trials in progress today after market close...
https://finance.yahoo.com/news/aptinyx-inc-host-earnings-call-201500829.html
👍️0
Moneta Man Moneta Man 4 years ago
Here's a link to the NYX-783 study in Phase II trials:
https://clinicaltrials.gov/ct2/show/NCT04044664?term=NYX-783&rank=1
👍️0
Moneta Man Moneta Man 4 years ago
Here's a link to the NYX-783 study in Phase II trials:
https://clinicaltrials.gov/ct2/show/NCT04044664?term=NYX-783&rank=1
👍️0
Moneta Man Moneta Man 4 years ago
Aptinyx is advancing a leading portfolio of novel CNS therapies - pretty exciting. Here's a link to current Phase II trials in the pipeline:
https://www.aptinyx.com/pipeline/
👍️0
Moneta Man Moneta Man 4 years ago
Aptinyx is advancing a leading portfolio of novel CNS therapies - pretty exciting. Here's a link to current Phase II trials in the pipeline:
https://www.aptinyx.com/pipeline/
👍️0
ClayTrader ClayTrader 4 years ago
* * $APTX Video Chart 10-20-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
crudeoil24 crudeoil24 4 years ago
APTX > Conference Call Information:

scheduled for 8:30 a.m. ET

To access the live conference call and webcast presentation, please dial (866) 939-3921 (U.S. Toll Free) or (678) 302-3550 (U.S. Toll) and refer to conference ID 49992933. A live audio and webcast presentation will be available on the Investors & Media section of Aptinyx's website at https://ir.aptinyx.com. A replay of the webcast will be archived on Aptinyx's website for 30 days following the event.
👍️0
crudeoil24 crudeoil24 4 years ago
New price targets, possibly above $10.00 in the forecast.

Aptinyx started at outperform with $7 stock price target at Wedbush
8:40 am ET September 12, 2019 (MarketWatch)
Share
Print
(END) Dow Jones Newswires
👍️0
realfast95 realfast95 4 years ago
bam too da moon
👍️0
ClayTrader ClayTrader 4 years ago
* * $APTX Video Chart 01-17-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
crudeoil24 crudeoil24 5 years ago
Aptinyx started at outperform with $7 stock price target at Wedbush
8:40 am ET September 12, 2019 (MarketWatch)
Share
Print
(END) Dow Jones Newswires

September 12, 2019 08:40 ET (12:40 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
👍️0
crudeoil24 crudeoil24 5 years ago
APTX > Aptinyx Inc. is a clinical-stage biopharmaceutical company. The Company discovers and develops therapies for disorders of the brain and nervous system. The Company has a platform for discovering compounds that work through a mechanism, which includes modulation of the N-methyl-D-aspartate (NMDA) receptor to develop pathways involved with nerve cell communication. The Company's compounds are effective on disease models including, depression, neuropathic pain, migraine, traumatic brain injury and age-induced learning impairment. The Company's compounds facilitate receptor activation without over-activating the receptor. The Company’s lead product candidate is NYX-2925, a treatment for the painful diabetic peripheral neuropathy. It is also developing NYX-783 for the treatment of post-traumatic stress disorder and NYX-458 for Parkinson’s disease cognitive impairment. The Company in partnership with Allergan plc, develops AGN-241751 for major depressive disorder indications.
👍️0